INFINITY PHARMACEUTICALS INC. : Infinity Reports Second Quarter 2013 ... 4-traders (press release) ... of a Phase 2, open-label, single-arm study designed to evaluate the safety and efficacy of IPI-145 dosed at 25 mg BID in approximately 120 patients with iNHL whose disease is refractory to radioimmunotherapy or to both rituximab and chemotherapy. |
